The judging panel consists of esteemed scientists across the USA that have demonstrated leadership in the sciences and innovation. They will make the final decisions on who will win services and what proposals will move on as finalists for the Facebook voting to be launched February 28, 2013.
Atul Butte MD, PhD
Division Chief and Associate Professor,
Stanford University School of Medicine
Atul Butte, MD, PhD is Chief of the Division of Systems Medicine and Associate Professor of Pediatrics, and by courtesy, Medicine and Computer Science, at Stanford University and Lucile Packard Children’s Hospital. Dr. Butte trained in Computer Science at Brown University, worked as a software engineer at Apple and Microsoft, received his MD at Brown University, trained in Pediatrics and Pediatric Endocrinology at Children’s Hospital Boston, then received his PhD in Health Sciences and Technology from Harvard Medical School and MIT. Dr. Butte is also a founder of Personalis, providing clinical interpretation of whole genome sequences, and NuMedii, finding new uses for drugs. Dr. Butte has authored more than 120 publications and delivered more than 140 invited presentations in personalized and systems medicine, biomedical informatics, and molecular diabetes. Dr. Butte’s research has been featured in the New York Times Science Times and the International Herald Tribune (2008), Wall Street Journal (2010 -2012), and San Jose Mercury News (2010). Dr. Butte’s recent awards include the 2012 FierceBiotech IT “Top 10 Biotech Techies”, 2011 National Human Genome Research Institute Genomic Advance of the Month, and the 2010 Society for Pediatric Research Young Investigator Award.
InnoThink Center for Research in Biomedical Innovation
Bernard H. Munos is the founder of the InnoThink Center for Research in Biomedical Innovation, a consultancy that focuses on pharmaceutical innovation — specifically, where it comes from and how to get more of it. He previously served as an advisor for corporate strategy at Eli Lilly and Company, where he focused on disruptive innovation and the radical redesign of research and development. His work has been published in Nature and Science, and was recently profiled by Forbes magazine. This year, the popular industry publication FiercePharma named him one of the 25 most influential people in biopharmaceuticals today. Munos received his MBA from Stanford University and holds graduate degrees in agricultural economics and animal science from the University of California, Davis, and the Paris Institute of Technology for Life, Food and Environmental Sciences. He is a Director of Phoenix Nest, a foundation dedicated to finding treatments for Sanfilippo syndrome, and serves on the Advisory Council and the Cures Acceleration Network Review Board of NIH’s National Center for Advancing Translational Sciences (NCATS). He is also a non-executive Director for Glenmark Pharmaceuticals, and advises companies, government-funded research organizations, and disease foundations on how to become better innovators.
Dr. Rienhoff is a San Francisco Bay area clinical scientist and entrepreneur. He was a partner directing biotechnology investments at the venture firm New Enterprise Associates. He was a founding director of such companies as Healtheon/WebMD (HLTH) and Aurora Biosciences (ABSC). In 1998, he founded DNA Sciences (originally Kiva Genetics), a company focused on genetic discoveries and served as its Chairman and CEO for 4 years. He is also Director of MyDaughtersDNA.org, an advocacy organization dedicated to understanding the genetics of rare diseases.
Dr. Rienhoff founded FerroKin BioSciences in 2007 and was Chief Executive Officer until its acquisition by Shire Pharmaceuticals in 2012. FerroKin BioSciences is developing a new treatment for transfusional iron overload, an orphan indication in the setting of rare hereditary and acquired anemias such as thalassemia major, sickle cell disease and myelodysplastic syndrome. Dr. Rienhoff is an Adjunct Scientist at the Children’s Hospital Oakland Research Institute and is a Visiting Scholar at the University of California at Berkeley. He trained in mathematics, medicine, and genetics at Harvard University, Johns Hopkins University, and the Fred Hutchinson Cancer Research Center in Seattle, Washington. He received a Doctor of Medicine degree from Johns Hopkins University School of Medicine and a Bachelor of Arts degree in Biology and English Literature from Williams College.
John F. Crowley, JD, MBA
President and Chief Executive Officer,
Mr. Crowley became president and CEO of Amicus in January 2005, having served as a director since 2004. Previously he was founding president and CEO of Orexigen Therapeutics. Preceding Orexigen, Mr. Crowley was senior vice president at Genzyme Therapeutics, a position he assumed after overseeing the sale of Novazyme Pharmaceuticals to Genzyme in September 2001. Mr. Crowley was the founding president and CEO of Novazyme that was developing a novel treatment for Pompe disease. He previously served in several senior management roles with the Bristol-Myers Squibb Company (BMS), including director of the Executive Committee for the U.S. Medicines Group, director of Business Strategy for the U.S. Pharmaceuticals Group, and director of U.S. Area Marketing for the Neuroscience and Infectious Disease Division. Preceding his experience at BMS, Mr. Crowley worked as a business strategy consultant for Marakon Associates. Mr. Crowley began his professional career as a litigation associate in the Health Care Practice Group of the Indianapolis-based law firm of Bingham, Summers, Welsh & Spilman.
Mr. Crowley is involved with several charitable and community organizations, including serving as president of the National Tay-Sachs and Allied Diseases Association. He is also on the Research Advisory Board of the national Muscular Dystrophy Association and the Board of Directors of St. Peter’s University Hospital. Mr. Crowley’s involvement with biotechnology stems from the 1998 diagnosis of two of his children with Pompe disease – a fatal neuromuscular disorder. Mr. Crowley and his family have been featured on the cover of The Wall Street Journal and on The Today Show, CNBC and The Paula Zahn Show.
Randall W. King, PhD
Harvard Medical School
Randall W. King MD, PhD is an Associate Professor in the Department of Cell Biology at Harvard Medical School, where his laboratory develops novel chemical tools to study ubiquitin-dependent protein breakdown and uses high-throughput siRNA screening to identify new genes required for cancer cell division. Prior to joining the faculty at Harvard Medical School, Dr. King was a fellow at the Institute of Chemistry and Cell Biology at Harvard, where he developed new approaches in chemical genetics, including instrumentation used for the synthesis and screening of arrayed split-pool chemical libraries. Dr.King co-founded the drug discovery company Kalypsys in 2001, and served on its science advisory board for four years. He received an MD from Harvard Medical School after receiving a PhD from Mark Kirschner’s laboratory at the University of California, San Francisco (UCSF). He received a B.A. degree in chemistry from Carleton College in 1987.
Technical Expert Team
The technical review panel consists of experts from sponsors of the Rare Disease Challenge. They will help judges determine the compatibility of submitted proposals with services and help answer any questions about their donated service.
Douglas E. Bassett, Jr.
Dr. Bassett is Chief Scientific Officer and Chief Technology officer at Ingenuity Systems (www.ingenuity.com). He received his Ph.D. from Johns Hopkins University in Human Genetics and was Executive Director, Molecular Profiling & Informatics at Merck & Co., Inc. prior to joining Ingenuity.
Donated Services: Ingenuity Variant Analysis to analyze 100 human whole genome or exome samples.
Areas of Expertise: Genetics, Informatics, Molecular Biology, Pharmaceutical R&D, Biomarker Discovery
The company was formed in December 2000 and is the premier provider of nucleic acid hybridization and thermodynamic solutions. Its OMPTM software is based on the pioneering research of its President and CEO, Dr. John SantaLucia, who is a Wayne State University professor, well-respected leader in his field, world-renowned consultant, and member of several national grant review committees. Dr. SantaLucia’s research has been cited by over 4000 publications. Dr. SantaLucia directs all of the company’s scientific endeavors.
Donated Services:Complete Visual OMP licenses for up to 100,000 qPCR data points to analyze 100 human whole genome or exome samples.
Dennis Meyer, DVM, DACVIM, DAVCP
Susan Y. Smith
Charles River Laboratories
Denny Meyer has an eclectic background comprised of clinical, research, investigational, and problem-solving experiences and managerial roles of increasing authority developed from 18 years in academia and 19 years in safety assessment of new chemical and biological entities (NCE, NBE). He has worked in both large and small pharmaceutical companies where he coordinated multi-focused research teams consisting of internal and external CRO and academic collaborations in support of drug development.
Susan Y. Smith is a Senior Scientific Director at Charles River with more than 25 years of experience. Her 15 years in nonclinical Bone Research has earned Susan the reputation as an expert in the field. She has co-authored more than 30 research papers in peer-reviewed scientific journals and contributed to chapters in several books related to skeletal research. At Charles River, she plays a key role in helping clients design studies that optimize their drug development programs.
Mark Vézina is the Scientific Director of the Ocular and Neuroscience Department at Charles River’s preclinical site in Montreal. With over 21 years experience he has authored/coauthored numerous publications and has lectured on various topics related to the development of ocular therapeutics at scientific conferences, academic institutions and pharma/biotech companies. Mark is an active member of the Ocular Toxicology Specialty Section of the Society of Toxicology (Past President) and a regular contributor to the Ocular Research Group on Linked-In.
Donated Services: Navigator Regulatory Consultation Services (Denny Meyer)in addition to Scientific Preclinical Program Design and Consultation Services, including specialty areas Bone (Susan Smith) and Ocular Research (Mark Vezina).
Mark Gustavson, Ph.D.
Mark Gustavson is Director of Operations for HistoRx. He leads the company’s scientific efforts for diagnostic assay development with academia and pharmaceutical companies using AQUA® technology for standardized and quantitative immunohistochemistry. Mark did his post-doctoral fellowship in the laboratory of Dr. David Rimm, Professor of Pathology at Yale University and Scientific Founder of HistoRx. Mark received his Ph.D. in Molecular Cancer Biology from Vanderbilt University School of Medicine.
Donated Services: antibody staining and quantitative immunohistochemistry (IHC).
Areas of Expertise: assay development, IHC, pathology
Karen Bingham, PhD
Ruth McLaughlin, PhD
Karen Bingham started with a BSc (Hons) in Molecular Biology from the University of Glasgow in 1993, followed by a PhD in the Cell Biology department (IBLS) at University of Glasgow. The project involved collaborations with the Electronic Engineering department at the University (joint “Cell Engineering” group) and was a CASE studentship sponsored by Ethicon, a Johnson & Johnson company. The aim of the project was to study the molecular mechanisms of cell shape changes and to develop a biodegradable implant for tendon repair. In June 2006 Karen joined Biopta Ltd. As Head of Operations Karen has day to day responsibility for the planning and running of the CRO side of the business.
Ruth McLaughlin has a BSc(Hons) Physiology, Sports Science and Nutrition from the University of Glasgow, followed by a PhD in Applied Physiology at the Universities of Strathclyde and Glasgow. Between 2006 and 2009 Ruth was employed by a CRO in Australia, where Ruth developed research opportunities, managed working relationships with key stakeholders and developed the Research Coordination Unit (RCU). As Head of the RCU, Ruth was responsible for the conduct and management of research projects. In March 2011 Ruth joined Biopta Ltd. As Business Development Manager Ruth is responsible for building existing relationship; generating new clients and new business and for managing and growing Biopta’s clinical network of tissue suppliers.
Graeme Macluskie has a BSc (Joint Hons) in Biochemistry and Pharmacology from the University of Strathclyde in 2001. From 2001 to 2011, he was employed by a leading CRO in the East of Scotland, whilst working in the Drug Metabolism and Pharmacokinetics department in both laboratory and supervisory roles. In May 2011 Graeme joined Biopta Ltd as an R&D scientist, working in expanding and refining Biopta’s current range of assays. Graeme has the responsibility for planning and running of internal studies and client studies.
Donated Services: Navigator Regulatory Consultation Services.
Areas of Expertise: Applied physiology; in vitro pharmacology; ethical and regulatory requirements, In vitro pharmacology, cell biology, molecular biology, in-vitro/in-vivo drug metabolism
Anna holds a BA from SUNY Bingham (1989) and a Ph.D. from the Interdisciplinary Neurosciences Program at Tulane University (1998). She served as the Director of the Environmental Institute’s Genomics Facility at Western Michigan University and has over 10 years of experience with state-of-the–art gene expression technologies.
Donated Services: gene expression or microRNA expression analysis.
Areas of Expertise: Molecular Biology
Josef Scheiber, PhD
Josef received his doctoral training at the Department of Pharmacy at the Julius-Maximilians-Universität. He postdoc’ed at the Novartis Institutes of Biomedical Research in Lead Discovery Informatics working on methods for in silico elucidation of adverse drug reactions, later becoming a Knowledge Engineer. In late 2009, he moved to Roche where he was working on Informatics projects at the interface of oncology and translational research. From April 2010 he was also a member of the global leadership team for Disease & Translational Informatics at Roche. In February 2012 he started working on his own venture – BioVariance – aiming to provide data analytics and tools for personalized healthcare.
Donated Services: 10 working days of consulting and data analysis.
Areas of Expertise: Bioinformatics, drug discovery, pharmacogenetics, oncology
Joanne Kamens is the Executive Director of Addgene, a mission driven, non-profit dedicated to helping scientists around the world collaborate. Dr. Kamens received her PhD in Genetics from Harvard Medical School then spent 15 years at BASF/Abbott where she led discovery research projects on inflammatory diseases. In 2007 she joined RXi Pharmaceuticals, later becoming Senior Director of Research Collaborations. She has been raising awareness of women scientists since 1998 upon realizing that an entire week had gone by at work and not one other woman had been at any meeting she attended. Dr. Kamens founded the Boston chapter of AWIS and served as a Director at large for the Healthcare Businesswomen’s Association Boston Chapter.
Donated Services: $5000 worth of reagent requests from their plasmid repository.
Areas of Expertise: immunology, inflammatory diseases, kinases, RNAi, antibody therapies
Regulated Bioanalysis and drug development
Bioanalytical expert with over 15 years of research and development experience, resulting in numerous publications, patents, and innovations that propel the advancement of science, medical treatment, and patient care. Strong scientific background, research capabilities, and business acumen that drive effective laboratory operations and project management. Serve as a proactive leader and team collaborator, motivate staff and establish a cohesive environment focused on accountability. Present complex information to diverse audiences as a technical subject matter expert (SME).
Donated Services: 10 hours of consulting services including technical writing, bioanalytical expertise, and project management.
Areas of Expertise: Regulated Bioanalysis and drug development